Heritage Investors Management Corp Sells 630 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Heritage Investors Management Corp trimmed its holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 1.2% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 53,500 shares of the company’s stock after selling 630 shares during the period. Heritage Investors Management Corp’s holdings in Teva Pharmaceutical Industries were worth $1,179,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in TEVA. Lingotto Investment Management LLP lifted its stake in shares of Teva Pharmaceutical Industries by 2.6% in the fourth quarter. Lingotto Investment Management LLP now owns 27,192,388 shares of the company’s stock worth $599,320,000 after buying an additional 688,862 shares during the last quarter. Todd Asset Management LLC acquired a new stake in shares of Teva Pharmaceutical Industries in the fourth quarter worth $58,243,000. Bank of New York Mellon Corp lifted its stake in shares of Teva Pharmaceutical Industries by 4.3% in the fourth quarter. Bank of New York Mellon Corp now owns 1,621,344 shares of the company’s stock worth $35,734,000 after buying an additional 67,571 shares during the last quarter. IFP Advisors Inc lifted its stake in shares of Teva Pharmaceutical Industries by 96.1% in the fourth quarter. IFP Advisors Inc now owns 3,999 shares of the company’s stock worth $88,000 after buying an additional 1,960 shares during the last quarter. Finally, Y Intercept Hong Kong Ltd acquired a new stake in shares of Teva Pharmaceutical Industries in the fourth quarter worth $2,868,000. 54.05% of the stock is owned by institutional investors.

Teva Pharmaceutical Industries Trading Down 2.7 %

Shares of TEVA stock opened at $16.32 on Friday. Teva Pharmaceutical Industries Limited has a 52-week low of $12.51 and a 52-week high of $22.80. The stock has a market cap of $18.49 billion, a price-to-earnings ratio of -11.26, a P/E/G ratio of 1.44 and a beta of 0.71. The company has a debt-to-equity ratio of 2.97, a quick ratio of 0.75 and a current ratio of 0.98. The firm has a fifty day moving average of $19.75 and a 200-day moving average of $18.48.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its quarterly earnings data on Wednesday, January 29th. The company reported $0.70 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.69 by $0.01. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. On average, equities research analysts forecast that Teva Pharmaceutical Industries Limited will post 2.5 earnings per share for the current fiscal year.

Insider Activity

In other news, Director Roberto Mignone sold 286,000 shares of the stock in a transaction on Friday, December 20th. The shares were sold at an average price of $22.01, for a total value of $6,294,860.00. Following the completion of the transaction, the director now owns 695,000 shares in the company, valued at approximately $15,296,950. This represents a 29.15 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 0.55% of the company’s stock.

Analyst Ratings Changes

TEVA has been the subject of a number of analyst reports. Barclays reduced their price objective on shares of Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating for the company in a research note on Thursday, January 30th. UBS Group cut their target price on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating for the company in a research note on Thursday, January 30th. StockNews.com cut shares of Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, December 18th. Finally, Piper Sandler upped their target price on shares of Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the company an “overweight” rating in a research note on Friday, January 17th. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $23.57.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.